SCHEMBL20239203

SCHEMBL20239203

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)nc(N)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.35
NUDT1 P36639 1/20 0.34
VNN1 O95497 1/20 0.33
PDE4B Q07343 1/20 0.33
MET P08581 1/20 0.33
KDR P35968 1/20 0.33
CYP3A4 P08684 1/20 0.33
HSP90AB1 P08238 1/20 0.32
CYP2C9 P11712 1/20 0.32
LMNA P02545 1/20 0.31
DHFR P00374 1/20 0.31
PPARG P37231 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738674 0.89 DGAT2 (0.57) DGAT2SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL20239204 0.89 DGAT2 (0.69) DGAT2SMN1; SMN2RAB9AALDH1A1MEN1
SCHEMBL20239333 0.89 DGAT2 (0.56) DGAT2SMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL20239227 0.88 DGAT2 (0.56) DGAT2SMN1; SMN2KDM4EVNN1CYP3A4
SCHEMBL20239171 0.88 DGAT2 (0.56) DGAT2SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL20239176 0.87 DGAT2 (0.55) DGAT2SMN1; SMN2RAB9AALDH1A1MEN1
SCHEMBL18249757 0.86 DGAT2 (0.54) DGAT2SMN1; SMN2KDM4EVNN1LMNA
SCHEMBL20239169 0.86 DGAT2 (0.54) DGAT2SMN1; SMN2ALDH1A1KDM4EVNN1
SCHEMBL20239261 0.85 DGAT2 (0.51) DGAT2SMN1; SMN2RAB9AALDH1A1MEN1
SCHEMBL20239272 0.85 DGAT2 (0.55) DGAT2SMN1; SMN2KDM4EVNN1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4828/4885RAB9A 1170/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4835/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.